TCG GreenChem Inc.’s Post

CPHI #CPHIMilan starts tomorrow, and we’re excited to be in attendance.     Learn more about the Aprecia vision:  ➡️ Imagine: Create new solutions and new possibilities in the digital age of medicine. ➡️ Inspire: Never stop exploring ways to take medicine to its fullest potential.  ➡️ Transform: Establish 3DP technology as a true digital pharmaceutical manufacturing technology.   Stop by and see us at booth #16F4 to learn more.    #AtTheHeartOfPharma #3Dprintingtechnology #pharmaceuticaltechnology 

Stop by the Aprecia Pharmaceuticals booth today to discuss how our 3DP Pharmaceutical Manufacturing Technology can help to solve your formulation challenges.

🎞 #LiveWithChaudhrey S05E193 with Abzena #18H11 Louise Duffy at CPHI Milan Oct 9th Day 2 It was lovely to catch up yesterday at #CPHIMilan with Louise who is Abzena's CTO and Chief Regulatory Officer to learn more about what they have been talking to visitors about this week in Milan, and some of the trends she has observed over the past 12momths, and what makes Abzena different to other CDMOs. There's still time to stop by the Abzena stand #18H11 to discuss your complex #biologic or #bioconjugate program with their experts during #CPHIMilan Take the opportunity to connect on your project-specific needs and an update on their expanded global #discovery, #development and #manufacturing capabilities. From #antibodies (#mAbs) to #recombinant #vaccines and #bioconjugates- including #ADCs, #radioconjugates, and #oligonucleotides, the team would like to share how #Abzena can assist in moving your program forward faster to its next milestone. Their team of experienced experts onsite will include: CCO, Joe Principe, Chief Technical and Quality Office, Louise Duffy, SVP & Scientific Leader, Dr. Petra Dieterich, DPhil, MBA, SVP of Global Marketing, Kimberly Burrell VP of Cell Line Development, Simon Keen, VP of Strategy, Gavin Murdoch Head of EU/ROW Sales, @Jonathan Cruikshank, VP of Business Development, Roger Bowie, VP of Business Development, Patrick Haddad, and VP of Business Development, Gildas Lavenant Can't make it today? You can meet the team 🤝 Next week at Festival of Biologics Basel 🤝 The week after at #AAPS #PharmSci360 #RSKCPHIMilan24 #RSKAbzena #CPHIWorldwide #DrugDevelopment #CDMO #CRO #Biopharma #Networking https://lnkd.in/ezaX-FYN

Check out our #LiveWithChaudhrey interview!

📅 #AConnex2024. Learn more about how we offer a comprehensive range of techniques and capabilities for pathology services, including the preparation and interpretation of histologic slides across multiple tissues and species essential for non-clinical research and development. #ERBCGroup #Lifescience #CRO #research #development #pathologyservices #pathologylab

Dear Esteemed Colleagues in the Pharmaceutical Industry, I trust this message finds you in good health and high spirits. I would like to convey my sincere best wishes to all esteemed peers who will be in attendance at CPhI Worldwide 2024 in Milan. The anticipation for the upcoming CPhI is palpable. I hope your participation in the event will yield fruitful outcomes, leading to the establishment of prosperous business partnerships for collective advancement. Given the limited timeframe of approximately 2.5 days for the event, it is imperative to thoughtfully arrange pre-scheduled meetings. Unfortunately, time constraints may restrict in-depth dialogues and the ability to meet all intended business associates. Nonetheless, we can leverage virtual platforms such as LinkedIn, telephone calls, WhatsApp, and Teams to engage in comprehensive discussions and interactions, transcending the constraints of physical meetings for those with whom an in-person meeting may not be feasible. While time is of the essence, it is crucial to nurture mutual understanding and cultivate robust professional relationships, recognizing each individual's pivotal role in the pharmaceutical landscape. I extend my sincere wishes for the success of all my colleagues at the upcoming CPhI 2024 event in Milan. Warm regards,

Could phage-based diagnostics prevent a post-antibiotic future? Drug-resistant Tuberculosis accounts for 1 in 3 deaths from antimicrobial resistance (AMR)*, meaning grim predictions for a ‘post-antibiotic age’ are already a reality for many countries. This is why a ‘test-of-cure’ diagnostic to extend the life of new drugs is so urgently needed. Dr Ben Swift is speaking today at  #BioInfect2024 says Actiphage could provide breakthrough test-of-cure for TB treatment AMR expert Dr Ben Swift, R&D Director for PBD Biotech says: “Our phage-based diagnostic has potential to monitor the efficacy of drug treatment – something not possible with current technology – as well as offering the opportunity to identify antibiotic-resistant TB.”   He explains that AMR occurs when microorganisms causing disease no longer respond to the drugs. “One of the reasons that AMR has increased for TB is that the traditional treatments require multiple drugs, taken over extended time periods. It is therefore difficult for many communities to gain access to the right medication, and patient compliance can be low as the drugs have severe side-effects.”   Tuberculosis disease is fatal if untreated and only about 2 in 5 people with drug resistant TB accessed treatment in 2022. A further 3.1 million cases remain undetected each year. The most widely used test for TB relies on measuring the patient’s immune response, which occurs when the disease is well progressed; the test also cannot distinguish between active disease and past infection.   PBD Biotech has developed Actiphage TB, which takes advantage of the specificity of interaction between a phage and its host bacteria to create a rapid diagnostic for TB and other diseases caused by Mycobacteria.   Actiphage is currently in lab user trials by the R2D2 Network in the Philippines. The country has a high incidence of TB and, in 2021, was one of the first to adopt BPaL, a new short-protocol medicine for multidrug-resistant TB.   Dr Swift continues: “BPaL is a six-month treatment that has been hailed as a breakthrough in the fight to End TB. In parallel with the development of new drugs, it is vital that new diagnostics are developed to target them effectively.   “By making the bacterial DNA available for sequencing, Actiphage would enable an informed choice of treatment for the patient, reducing the risk of resistance. Additionally, as Actiphage detects only live mycobacteria it can also be used after the course of treatment as a test-of-cure and to support the development of new drugs.”   Dr Swift will be discussing the role of phage-based TB diagnostics in the ‘What’s in the pipeline’ session of BioInfect 2024 on Thursday 8th February 2024 at The Spine, Liverpool L7 3FA.   Further information for the event can be found at https://lnkd.in/e727TAEJ  #tuberculosis #EndTb. #Bionow. #Bioinfect #pathology   * https://lnkd.in/eZr9VC7v

Linking you with pharma resources via our professionalism.

CPhI Frankfurt 🇩🇪 2025 👇 Stand selection tips to CDMOs 👇 Some may or may not know that on July 22, 2024, CDMOs will be able to select their space for CPhI Frankfurt 2025 (CPhI Worldwide) to be held from Oct. 28-30, 2025. I encourage those in the CDMO business and their customers to encourage CDMOs to select stands in Hall 6 and Hall 5 (I can recommend Hall 6.1 ). WHY? The best events are when you have lots of meetings. Customers (potential or existing) do NOT want to get their steps in by walking all over from one hall to another on the other side of the venue. As part of the service side of the pharma industry, it is time to service customers at events by making it convenient for them to schedule meetings without factoring in time to walk 🚶♂️ 20 minutes 😓 to another meeting. I encourage you to connect with your team that does the selection of stand location and share this information. A little planning now will lead to a successful CPhI for all of us. 👍 💯 #CPhI #CPhIFrankfurt #CPhIFrankfurt2025 #CDMO #Flamma #ThinkingCDMO

Not long to go until ADLM! Come and visit Biofortuna at booth 3157, or book a meeting in advance (https://bit.ly/3SdjWjU), to: ✅ Explore how our customised genomics services can propel your research forward. ✅ Discover how we facilitate molecular diagnostics development through adaptable assay design. ✅ Gain insights into how Lyophilised beads can streamline your assay development process and enhance product stability. ✅ Share your specific requirements for manufacturing IVD kits. Our team is eager to share their experience and explore how we can support your scientific and clinical goals. #ADLM #AssayDevelopment #Chicago #MolecularDiagnostics #Lyophilization